NGS Archives – Beacon Medical Interchange

Dr. Jean-Charles (Pt 2): Transitioning from Life in Paris to the US and from Academia to Industry

Dr. Jean-Charles Soria reviews the challenge in academic research of “champagne dreams on a beer budget”, his decision to pursue a research leadership role at AZ, & shares his vision of a future of molecular oncology & a growing role for liquid biopsies. (23:39)

Dr. Ross Camidge (Pt 1): Working at the Forefront of Developing New Targets and New Therapies

Dr. Ross Camidge from the University of Colorado discusses his career trajectory, how cancer research in narrow molecularly defined populations has evolved, challenges in molecular oncology practice, & the brain as a new frontier for treatment efficacy. (24:40)

Dr. Greg Riely (Pt 1): Current Practice & Challenges in Execution of Genomic Testing in Lung Cancer Treatment

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center (MSKCC) chats with Dr. Jack West about current standards in molecular testing for advanced NSCLC & potential challenges in execution in translating the promise of genomics into broad practice. (19:57)

Dr. Alex Drilon: Clinical Research and the Changing Practice of Managing Molecularly-Defined, Narrow Subgroups

Drs. Jack West & Alex Drilon, from Memorial Sloan-Kettering, discuss opportunities & challenges of studying narrow molecularly-defined patient subgroups, (MET, RET, TRK, & others), along with the increasingly active role of online patient groups. (12:17)

Dr. David Spigel, Part 1: Clinical Research and the Growing Complexity of Cancer Care in a Community Setting

Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine. (24:32)

Genomic Sequencing for All Solid Tumors: Where Will This Lead Us? (BMIC-019)

Dr. Jack West reviews the implications, both encouraging and potentially detrimental, of a recent FDA approval for broad genomic (NGS) testing of all solid tumors, ushering in a new era of growing precision medicine and molecular oncology. (8:55)

Download MP3 Audio Version

New Target & Treatment in Advanced NSCLC: Dabrafenib/Trametinib for BRAF V600E Mutation-Positive NSCLC (BMIC-018)

Dr. Jack West reviews data on the FDA-approved combination of dabrafenib/trametinib for patients with BRAF V600E mutation-positive advanced NSCLC, as published by Planchard & colleagues in Lancet Oncology. (6:24)